Targeting the root biology of heart failure
Heart failure is driven by two coupled deficits – impaired energy production and weakened contraction. In preclinical models, Vectorial’s molecule enters cardiac muscle cells, activates a native master regulator of energy and mechanical performance, and restores function throughout the cardiac contraction cycle.
Helping hearts beat stronger again by restoring energy and strength.
01
Enhancing mitochondrial function and cardiac energetics
The human heart contracts more than 100,000 times per day and depends on a substantial, continuous supply of ATP (~6 kg/day). Targeted cardiac gene delivery enhances mitochondrial biogenesis, oxidative capacity, and ATP production – restoring energetic reserve within physiologically safe limits.
02
Enhancing contractile function
Heart failure is a self-reinforcing cycle of metabolic and mechanical decline. Existing therapies primarily target neurohormonal signals; they do not restore intrinsic cardiomyocyte performance. Mechanism-driven gene therapy enables simultaneous improvement in mitochondrial energetics and mechanical performance – preserving systolic function and attenuating adverse remodeling under pathological stress.
03
Sustaining cardiac performance under pathological stress
Pathological stress disrupts substrate utilization and limits cardiac reserve. Preclinical data show that targeted gene delivery preserves mitochondrial respiratory capacity across varying energetic demands – supporting consistent output and improved functional resilience. By addressing the underlying bioenergetic deficits that drive disease progression, this approach offers a durable therapeutic strategy beyond symptomatic management.
Targeting the root biology of heart failure
Heart failure is driven by two coupled deficits – impaired energy production and weakened contraction. In preclinical models, Vectorial’s molecule enters cardiac muscle cells, activates a native master regulator of energy and mechanical performance, and restores function throughout the cardiac contraction cycle.
01
Enhancing mitochondrial function and cardiac energetics
The human heart contracts more than 100,000 times per day and depends on a substantial, continuous supply of ATP (~6 kg/day). Targeted cardiac gene delivery enhances mitochondrial biogenesis, oxidative capacity, and ATP production – restoring energetic reserve within physiologically safe limits.
02
Enhancing contractile function
Heart failure is a self-reinforcing cycle of metabolic and mechanical decline. Existing therapies primarily target neurohormonal signals; they do not restore intrinsic cardiomyocyte performance. Mechanism-driven gene therapy enables simultaneous improvement in mitochondrial energetics and mechanical performance – preserving systolic function and attenuating adverse remodeling under pathological stress.
03
Sustaining cardiac performance under pathological stress
Pathological stress disrupts substrate utilization and limits cardiac reserve. Preclinical data show that targeted gene delivery preserves mitochondrial respiratory capacity across varying energetic demands – supporting consistent output and improved functional resilience. By addressing the underlying bioenergetic deficits that drive disease progression, this approach offers a durable therapeutic strategy beyond symptomatic management.
Peer-reviewed publications
In preclinical models of cardiac stress, targeted gene delivery preserved left ventricular systolic function and prevented structural remodeling associated with heart failure progression. Mitochondrial respiratory capacity remained stable under energetic demand, and cardiac performance was maintained relative to baseline. These findings support continued development of a mechanism-driven gene therapy approach designed to restore energetic capacity and contractile performance in the failing heart.